Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products.
暂无分享,去创建一个
C. Angeletti | G. Fontanini | A. Mussi | M. Lucchi | G. Bevilacqua | D. Bigini | S. Vignati | S. Chine | Aifredo Mussi
[1] A. Harris,et al. Microvessel count predicts metastatic disease and survival in non‐small cell lung cancer , 1995, The Journal of pathology.
[2] N. Weidner. Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.
[3] C. Angeletti,et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.
[4] H. Joensuu,et al. Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.
[5] G. Niehans,et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. , 1994, Journal of the National Cancer Institute.
[6] S. Nasim,et al. Prognostic significance of p53 overexpression in endometrial cancer. , 1994, Cancer research.
[7] U. Veronesi,et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.
[8] A. Harris,et al. Clinical prognostic significance of tumour angiogenesis. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] F. Rilke,et al. Bcl‐2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland , 1994, The Journal of pathology.
[10] H. Katz. bcl-2 protein in non-small-cell lung carcinoma. , 1994, The New England journal of medicine.
[11] A. Harris,et al. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. , 1994, British Journal of Cancer.
[12] N. Weidner,et al. Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma , 1993, International journal of cancer.
[13] A. Ghosh,et al. Volunteer Duty , 1993, Environmental Health Perspectives.
[14] D. Chopin,et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.
[15] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[16] G. Gibson,et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. , 1993, British Journal of Cancer.
[17] U. Veronesi,et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.
[18] C. Angeletti,et al. p53 expression in non small cell lung cancer: clinical and biological correlations. , 1993, Anticancer research.
[19] W. McGuire,et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.
[20] A. Harris,et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.
[21] D. Quinlan,et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.
[22] C. Angeletti,et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.
[23] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[24] E. Kawasaki,et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.
[25] J. Monson,et al. Is the relationship between angiogenesis and metastasis in breast cancer real? , 1992, Surgical oncology.
[26] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[27] S. Rodenhuis,et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.
[28] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[29] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[30] R. Tsuchiya,et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.
[31] C. Mountain,et al. A new international staging system for lung cancer. , 1987, Chest.
[32] H Stein,et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[33] K. Chew,et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. , 1995, Journal of the National Cancer Institute.
[34] J. Folkman. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.
[35] 山崎 浩一. Tumor angiogenesis in human lung adenocarcinoma , 1995 .
[36] G. Scagliotti,et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. , 1993, European journal of cancer.
[37] M. Gerretsen,et al. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.
[38] The World Health Organization. Histological typing of lung tumours. , 1982, Neoplasma.